ATE402999T1 - Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung - Google Patents

Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Info

Publication number
ATE402999T1
ATE402999T1 AT03731644T AT03731644T ATE402999T1 AT E402999 T1 ATE402999 T1 AT E402999T1 AT 03731644 T AT03731644 T AT 03731644T AT 03731644 T AT03731644 T AT 03731644T AT E402999 T1 ATE402999 T1 AT E402999T1
Authority
AT
Austria
Prior art keywords
igfbp
antisense oligonucleotides
inhibit
bispecific antisense
bispecific
Prior art date
Application number
AT03731644T
Other languages
English (en)
Inventor
Martin Gleave
Maxim Signaevsky
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE402999T1 publication Critical patent/ATE402999T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03731644T 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung ATE402999T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17

Publications (1)

Publication Number Publication Date
ATE402999T1 true ATE402999T1 (de) 2008-08-15

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731644T ATE402999T1 (de) 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Country Status (15)

Country Link
US (11) US20030158143A1 (de)
EP (1) EP1465995B1 (de)
JP (1) JP4491240B2 (de)
KR (2) KR101166214B1 (de)
AT (1) ATE402999T1 (de)
AU (1) AU2003237616B2 (de)
CA (1) CA2469685C (de)
DE (1) DE60322509D1 (de)
DK (1) DK1465995T3 (de)
ES (1) ES2307942T3 (de)
HU (1) HU229452B1 (de)
IL (2) IL162540A0 (de)
NO (1) NO333017B1 (de)
NZ (1) NZ533126A (de)
WO (1) WO2003062421A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
ATE478142T1 (de) * 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
EP1560933A4 (de) * 2002-11-14 2007-11-21 Wyeth Corp Verfahren und zusammensetzungen zur behandlung neurologischer erkrankungen
EP1667731B1 (de) * 2003-10-01 2013-05-22 The University Of British Columbia Bispezifisches oligonucleotid zur behandlung von malignen zns-erkrankungen
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
SG183114A1 (en) 2010-03-01 2012-09-27 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2012156817A2 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
SG10201601917XA (en) 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
EA201491568A1 (ru) 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
US9744187B2 (en) * 2015-10-14 2017-08-29 Bio-Path Holdings, Inc. p-Ethoxy nucleic acids for liposomal formulation
EP3364993B1 (de) 2015-10-22 2022-11-09 Cavion, Inc. Verfahren zur behandlung des angelman-syndroms
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
EP3512525B1 (de) 2016-09-16 2022-07-27 Bio-Path Holdings, Inc. Kombinationstherapie mit liposomalen antisense-oligonukleotiden
EP3585376A4 (de) 2017-02-15 2020-11-25 Cavion, Inc. Calciumkanalinhibitoren
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
US11041153B2 (en) 2017-04-19 2021-06-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition
KR102654466B1 (ko) 2017-04-26 2024-04-08 카비온, 인코포레이티드 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
EP3860571A4 (de) 2018-10-03 2022-06-29 Cavion, Inc. Behandlung von essentiellem tremor unter verwendung von (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluorethoxy)pyridin-2-yl)ethyl)acetamid

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546110B1 (de) 1990-08-28 2001-11-14 Chiron Corporation Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
EP0546074B1 (de) 1990-08-28 2001-11-14 Chiron Corporation Genetisches igfbp-5 rodierendes material
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE69432315T2 (de) * 1993-12-23 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
CA2246229C (en) * 1996-02-14 2011-08-23 Isis Pharmaceuticals Inc. Sugar-modified gapped oligonucleotides
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
JP3687900B2 (ja) 1998-11-19 2005-08-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
ATE393220T1 (de) * 1999-07-19 2008-05-15 Univ British Columbia Antisense-therapie für hormonregulierte tumoren
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
NZ553687A (en) * 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
EP1317470B1 (de) * 2000-09-14 2011-04-27 The University Of British Columbia Antisense insulin-ähnliches wachstumsfaktor bindendes protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
EP1390472A4 (de) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
WO2003097855A2 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
ATE478142T1 (de) 2002-08-21 2010-09-15 Univ British Columbia Behandlung von melanomen durch reduktion der clusterin menge
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
EP1667731B1 (de) * 2003-10-01 2013-05-22 The University Of British Columbia Bispezifisches oligonucleotid zur behandlung von malignen zns-erkrankungen
BR112012002102A2 (pt) * 2009-07-30 2017-05-02 Antisense Pharma Gmbh composição farmaceutica e metodo para preparar uma composição farmaceutica

Also Published As

Publication number Publication date
US20120220646A1 (en) 2012-08-30
US20130303592A1 (en) 2013-11-14
HU229452B1 (en) 2013-12-30
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
CA2469685A1 (en) 2003-07-31
US8580761B2 (en) 2013-11-12
HUP0402543A2 (hu) 2005-03-29
US8470796B2 (en) 2013-06-25
US20160002630A1 (en) 2016-01-07
US9101646B2 (en) 2015-08-11
AU2003237616B2 (en) 2007-07-05
NZ533126A (en) 2006-04-28
IL162540A (en) 2011-06-30
US8835401B2 (en) 2014-09-16
IL162540A0 (en) 2005-11-20
HUP0402543A3 (en) 2012-09-28
US20060122141A1 (en) 2006-06-08
KR101265180B1 (ko) 2013-05-29
NO333017B1 (no) 2013-02-18
US20110196019A1 (en) 2011-08-11
US8252765B2 (en) 2012-08-28
US20080261912A1 (en) 2008-10-23
ES2307942T3 (es) 2008-12-01
US8541390B2 (en) 2013-09-24
JP4491240B2 (ja) 2010-06-30
DE60322509D1 (de) 2008-09-11
CA2469685C (en) 2013-03-12
DK1465995T3 (da) 2008-10-20
EP1465995B1 (de) 2008-07-30
KR20040085150A (ko) 2004-10-07
NO20043401L (no) 2004-10-13
EP1465995A1 (de) 2004-10-13
US20100267808A1 (en) 2010-10-21
KR101166214B1 (ko) 2012-07-16
US7973017B2 (en) 2011-07-05
US20030158143A1 (en) 2003-08-21
US7928082B2 (en) 2011-04-19
US20130096180A1 (en) 2013-04-18
US20110190382A1 (en) 2011-08-04
WO2003062421A1 (en) 2003-07-31
JP2005514948A (ja) 2005-05-26
US20120077861A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
DE60322509D1 (de) Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
IL197159A (en) Two-stranded rna molecules that complement a sense or antisense strand of a human encoding igfbp-2 and igfbp-5, preparations containing them and their uses
DE60211937D1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
EP1412371A4 (de) IN-VIVO-HERSTELLUNG VON KLEINEN INTERFERIERENDEN RNAs, DIE DAS ABSCHALTEN VON GENEN VERMITTELN
DE60317663D1 (de) Fluorchemische zusammensetzung enthaltend einen fluorierten polyether und dessen verwendung zur behandlung von fasermaterialien
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
HRP20070189A2 (en) Use of erythropoietin
ATE418336T1 (de) Verwendung von i kappa b-kinase inhibitoren in der schmerztherapie
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
SI1575951T1 (sl) Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
MY136822A (en) Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
BG105779A (bg) Човешки антибиотични протеини
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
EP1601325A4 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
NO20053903D0 (no) Nukleotidlipidesterderivater.
ATE533779T1 (de) Isoliertes photoprotein mtclytin, sowie dessen verwendung
EP1610807A4 (de) Verwendung von wiederholungssequenz-protein-polymeren in körperpflegezusammensetzungen
AU309683S (en) Massaging belt
GB0306635D0 (en) Improvements in or relating to hair care

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465995

Country of ref document: EP